346691-01-8

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, [(3R)-1-methyl-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) is used as a chiral building block for the synthesis of various pharmaceuticals. Its enantiomerically pure form allows for the creation of complex organic molecules with specific biological activities, contributing to the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, Carbamic acid, [(3R)-1-methyl-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) is utilized in the production of agrochemicals. Its chiral properties enable the synthesis of molecules with targeted effects on pests or crops, enhancing the efficiency and selectivity of these products.
Used in Flavors and Fragrances Industry:
Carbamic acid, [(3R)-1-methyl-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) is employed as a chiral building block in the creation of flavors and fragrances. Its ability to form complex organic molecules contributes to the development of unique and distinct scents and tastes for various applications.
Used in Asymmetric Synthesis Research:
Carbamic acid, [(3R)-1-methyl-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) has been studied for its potential as a chiral auxiliary in asymmetric synthesis. Its use in research helps to advance the understanding of chiral chemistry and contributes to the development of more efficient and selective synthetic methods.

Upstream product

• 50-00-0 formaldehyd 
• 122536-77-0 3-N-tert-butoxycarbonyl-3-(R)-aminopyrrolidine 
• 131878-23-4 (3R)-1-benzyl-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1209287-84-2 1-methyl-3-(R)-aminopyrrolidine dihydrochloride 
• 1359969-58-6 2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-N-((R)-1-methylpyrrolidin-3-yl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinoline-7-carboxamide 
• 346690-76-4 (R)-1-methylpyrrolidine-3-amine hydrochloride 
• 1359969-55-3 2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-N-methyl-N-((R)-1-methylpyrrolidin-3-yl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinoline-7-carboxamide 
• 792970-21-9 (R)-N,1-dimethylpyrrolidine-3-amine 

Relevant academic research and scientific papers

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

The present disclosure is directed to compounds of formula I and methods of their use and preparation, as well as compositions comprising compounds of formula I.

FUSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONIST

The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y1, Y2, Y3, R1, R2a,R2b , R3a , R3b, R4, Cy and n are as presented in the description.

Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist

The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4, Cy and n are as presented in the description.

2H-PYRAZOLO [4,3-D]PYRIMIDIN-5-AMINE DERIVATIVES AS H4 HISTAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGIC, IMMUNOLOGICAL AND INFLAMMATORY DISEASES

Pyrazolopyrimidine derivatives of formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.

PIPERIDIN-PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H4 RECEPTOR

Piperidin-pyrimidine derivatives of formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.

FURO[3,2-D]PYRIMIDINE DERIVATIVES

Furo[3,2-d]pyrimidine derivatives of formula I, wherein the meanings for the various substituents are as defined in the description. These compounds are useful as H4 receptor antagonists.

2 -AMINO-PYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS

2-Aminopyrimidine derivatives of formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.

ORGANIC COMPOUNDS

Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I)and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

NOVEL COMPOUNDS

There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.